{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:44:28Z","timestamp":1792647868009,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":1132,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007186","name":"Jonsson Comprehensive Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007186","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011075","name":"David Geffen School of Medicine, University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008590","name":"Dr. Ralph and Marian Falk Medical Research Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008590","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002077","name":"Epidermolysis Bullosa Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002077","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008163","name":"A-T Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008163","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016951","name":"UCLA AIDS Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016951","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01NS052528"],"award-info":[{"award-number":["1R01NS052528"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI-28697"],"award-info":[{"award-number":["AI-28697"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA-16042"],"award-info":[{"award-number":["CA-16042"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1038\/mt.2013.150","type":"journal-article","created":{"date-parts":[[2013,6,18]],"date-time":"2013-06-18T07:10:54Z","timestamp":1371539454000},"page":"1653-1660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["A New Series of Small Molecular Weight Compounds Induce Read Through of All Three Types of Nonsense Mutations in the ATM Gene"],"prefix":"10.1016","volume":"21","author":[{"given":"Liutao","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Damoiseaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gladys","family":"Completo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Mo","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shareef","family":"Nahas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cijing","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2013.150_bib1","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0092-8674(01)00583-9","article-title":"When the message goes awry: disease-producing mutations that influence mRNA content and performance","volume":"107","author":"Mendell","year":"2001","journal-title":"Cell"},{"key":"10.1038\/mt.2013.150_bib2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/1531-8249(200008)48:2<164::AID-ANA5>3.0.CO;2-B","article-title":"Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy","volume":"48","author":"Howard","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1038\/mt.2013.150_bib3","doi-asserted-by":"crossref","first-page":"6885","DOI":"10.1074\/jbc.M806728200","article-title":"Poly-L-aspartic acid enhances and prolongs gentamicin-mediated suppression of the CFTR-G542X mutation in a cystic fibrosis mouse model","volume":"284","author":"Du","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2013.150_bib4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.clpt.6100012","article-title":"Aminoglycoside-induced translational read-through in disease: overcoming nonsense mutations by pharmacogenetic therapy","volume":"81","author":"Zingman","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1038\/mt.2013.150_bib5","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/wrna.95","article-title":"Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases","volume":"2","author":"Keeling","year":"2011","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"10.1038\/mt.2013.150_bib6","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1084\/jem.20081940","article-title":"Nonaminoglycoside compounds induce readthrough of nonsense mutations","volume":"206","author":"Du","year":"2009","journal-title":"J Exp Med"},{"key":"10.1038\/mt.2013.150_bib7","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1093\/hmg\/ddr217","article-title":"Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum","volume":"20","author":"Du","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1038\/mt.2013.150_bib8","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1165\/rcmb.2001-0004OC","article-title":"Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis","volume":"27","author":"Ramalho","year":"2002","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1038\/mt.2013.150_bib9","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1093\/hmg\/5.12.2033","article-title":"Ataxia-telangiectasia: founder effect among north African Jews","volume":"5","author":"Gilad","year":"1996","journal-title":"Hum Mol Genet"},{"key":"10.1038\/mt.2013.150_bib10","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/01.mcp.0000141247.22078.46","article-title":"Pharmacologic therapy for stop mutations: how much CFTR activity is enough?","volume":"10","author":"Kerem","year":"2004","journal-title":"Curr Opin Pulm Med"},{"key":"10.1038\/mt.2013.150_bib11","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.dnarep.2004.04.010","article-title":"Ataxia-telangiectasia, an evolving phenotype","volume":"3","author":"Chun","year":"2004","journal-title":"DNA Repair (Amst)"},{"key":"10.1038\/mt.2013.150_bib12","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1093\/hmg\/dds223","article-title":"Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy","volume":"21","author":"Kayali","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1038\/mt.2013.150_bib13","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1073\/pnas.0711795105","article-title":"PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model","volume":"105","author":"Du","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2013.150_bib14","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/nm1197-1280","article-title":"Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line","volume":"3","author":"Bedwell","year":"1997","journal-title":"Nat Med"},{"key":"10.1038\/mt.2013.150_bib15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nm0496-467","article-title":"Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations","volume":"2","author":"Howard","year":"1996","journal-title":"Nat Med"},{"key":"10.1038\/mt.2013.150_bib16","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1161\/01.ATV.0000118683.99628.42","article-title":"Absence of dystrophin in mice reduces NO-dependent vascular function and vascular density: total recovery after a treatment with the aminoglycoside gentamicin","volume":"24","author":"Loufrani","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1038\/mt.2013.150_bib17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/hmg\/10.3.291","article-title":"Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation","volume":"10","author":"Keeling","year":"2001","journal-title":"Hum Mol Genet"},{"key":"10.1038\/mt.2013.150_bib18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/sj.ejhg.5200599","article-title":"Premature termination mutations in exon 3 of the SMN1 gene are associated with exon skipping and a relatively mild SMA phenotype","volume":"9","author":"Sossi","year":"2001","journal-title":"Eur J Hum Genet"},{"key":"10.1038\/mt.2013.150_bib19","doi-asserted-by":"crossref","first-page":"15676","DOI":"10.1073\/pnas.0405155101","article-title":"Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons","volume":"101","author":"Lai","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2013.150_bib20","first-page":"15","article-title":"Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results","volume":"22","author":"Politano","year":"2003","journal-title":"Acta Myol"},{"issue":"3 Pt 1","key":"10.1038\/mt.2013.150_bib21","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1164\/ajrccm.161.3.9904116","article-title":"A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations","volume":"161","author":"Wilschanski","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1038\/mt.2013.150_bib22","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1164\/ajrccm.163.7.2004001","article-title":"Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis","volume":"163","author":"Clancy","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1038\/mt.2013.150_bib23","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/AAC.43.5.1003","article-title":"Aminoglycosides: nephrotoxicity","volume":"43","author":"Mingeot-Leclercq","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1038\/mt.2013.150_bib24","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/hmg\/9.12.1787","article-title":"A biochemical basis for the inherited susceptibility to aminoglycoside ototoxicity","volume":"9","author":"Guan","year":"2000","journal-title":"Hum Mol Genet"},{"key":"10.1038\/mt.2013.150_bib25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/gut.2008.169805","article-title":"Restoration of APC gene function in colorectal cancer cells by aminoglycoside- and macrolide-induced read-through of premature termination codons","volume":"59","author":"Zilberberg","year":"2010","journal-title":"Gut"},{"key":"10.1038\/mt.2013.150_bib26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"10.1038\/mt.2013.150_bib27","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/0091270006297140","article-title":"Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers","volume":"47","author":"Hirawat","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1038\/mt.2013.150_bib28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.coph.2010.03.005","article-title":"Molecular treatments in Duchenne muscular dystrophy","volume":"10","author":"Guglieri","year":"2010","journal-title":"Curr Opin Pharmacol"},{"key":"10.1038\/mt.2013.150_bib29","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1016\/j.bmcl.2011.07.107","article-title":"Synthesis and evaluation of compounds that induce readthrough of premature termination codons","volume":"21","author":"Jung","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1038\/mt.2013.150_bib30","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1067\/mpd.2002.123879","article-title":"Early diagnosis of ataxia-telangiectasia using radiosensitivity testing","volume":"140","author":"Sun","year":"2002","journal-title":"J Pediatr"},{"key":"10.1038\/mt.2013.150_bib31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00063030-200923030-00003","article-title":"Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development","volume":"23","author":"Rowe","year":"2009","journal-title":"BioDrugs"},{"key":"10.1038\/mt.2013.150_bib32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1749-6632.2012.06467.x","article-title":"SMRT compounds correct nonsense mutations in primary immunodeficiency and other genetic models","volume":"1250","author":"Gatti","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1038\/mt.2013.150_bib33","doi-asserted-by":"crossref","first-page":"E144","DOI":"10.1038\/ncb0602-e144","article-title":"RNA surveillance by nuclear scanning?","volume":"4","author":"Wilkinson","year":"2002","journal-title":"Nat Cell Biol"},{"key":"10.1038\/mt.2013.150_bib34","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/ng1403","article-title":"Nonsense-mediated decay approaches the clinic","volume":"36","author":"Holbrook","year":"2004","journal-title":"Nat Genet"},{"key":"10.1038\/mt.2013.150_bib35","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI28523","article-title":"Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin","volume":"117","author":"Linde","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1038\/mt.2013.150_bib36","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1023\/A:1009637512917","article-title":"ATM dependent apoptosis in the nervous system","volume":"5","author":"Lee","year":"2000","journal-title":"Apoptosis"},{"key":"10.1038\/mt.2013.150_bib37","first-page":"225","article-title":"Cerebellar pathology in ataxia-telangiectasia: the significance of basket cells","volume":"19","author":"Gatti","year":"1985","journal-title":"Kroc Found Ser"},{"key":"10.1038\/mt.2013.150_bib38","first-page":"233","article-title":"Sequence of cellular events in cerebellar ontogeny relevant to expression of neuronal abnormalities in ataxia-telangiectasia","volume":"19","author":"Vinters","year":"1985","journal-title":"Kroc Found Ser"},{"key":"10.1038\/mt.2013.150_bib39","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/ncomms2824","article-title":"SMRT compounds abrogate cellular phenotypes of ataxia telangiectasia in neural derivatives of patient-specific hiPSCs","volume":"4","author":"Lee","year":"2013","journal-title":"Nat Commun"},{"key":"10.1038\/mt.2013.150_bib40","first-page":"139","article-title":"Rapid screen for truncating ATM mutations by PTT-ELISA","volume":"640","author":"Du","year":"2008","journal-title":"Mutat Res"},{"key":"10.1038\/mt.2013.150_bib41","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1373\/clinchem.2008.107128","article-title":"Rapid flow cytometry-based structural maintenance of chromosomes 1 (SMC1) phosphorylation assay for identification of ataxia-telangiectasia homozygotes and heterozygotes","volume":"55","author":"Nahas","year":"2009","journal-title":"Clin Chem"},{"key":"10.1038\/mt.2013.150_bib42","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.1073\/pnas.0608616104","article-title":"Correction of prototypic ATM splicing mutations and aberrant ATM function with antisense morpholino oligonucleotides","volume":"104","author":"Du","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2013.150_bib43","first-page":"2544","article-title":"Radiosensitivity of ataxia-telangiectasia, X-linked agammaglobulinemia, and related syndromes using a modified colony survival assay","volume":"54","author":"Huo","year":"1994","journal-title":"Cancer Res"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616319992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616319992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:04:40Z","timestamp":1778616280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616319992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1525001616319992"],"URL":"https:\/\/doi.org\/10.1038\/mt.2013.150","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A New Series of Small Molecular Weight Compounds Induce Read Through of All Three Types of Nonsense Mutations in the ATM Gene","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/mt.2013.150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}